Edarbyclor Tablet
Product Images NDC 75929-230

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Edarbyclor (NDC 75929-230). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pharma Packaging Solutions, Llc Dba Tjoapack Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle1 (Bottle1)

Bottle1 (Bottle1)
FDA Label Image

Figure 1.a (Edarbyclor 01)

Figure 1.a (Edarbyclor 01)
FDA Label Image

Figure 1.b (Edarbyclor 02)

Figure 1.b (Edarbyclor 02)
Not available*
FDA Label Image

Figure 1.c (Edarbyclor 03)

Figure 1.c (Edarbyclor 03)
This is a blood pressure chart that shows the diastolic blood pressure readings in millimeters of mercury (mmHg) at different points. The text indicates that the diastolic blood pressure should be less than 90 mmHg (9%) for optimal health. The chart also includes the names and doses of certain medications such as Edarbyclor (40/25mg), Azilsartan medoxomil (80mg), and Chlorthalidone (25mg). The "Baseline Diastolic BP" refers to the initial diastolic blood pressure measurement.*
FDA Label Image

Figure 1.d (Edarbyclor 04)

Figure 1.d (Edarbyclor 04)
FDA Label Image

Chemical Structure (Edarbyclor 05)

Chemical Structure (Edarbyclor 05)
FDA Label Image

Chemical Structure (Edarbyclor 06)

Chemical Structure (Edarbyclor 06)
FDA Label Image

Figure 2 (Edarbyclor 07)

Figure 2 (Edarbyclor 07)
Population Description: This description provides information about the population involved in a study or evaluation. It includes details such as age range (greater than 65 years or 18-45 years), gender (females or males), race (whites or blacks), renal impairment severity (mild, moderate, severe, or end-stage renal disease), hepatic impairment severity (mild, moderate, severe, or normal), and the presence of pediatric patients. Based on the text, there are also recommendations for dose adjustment, with the notation "No dose adjustment" being mentioned multiple times. Furthermore, there is an indication of "No experience" in certain cases. Overall, this text provides a description of the studied population's characteristics and recommendations related to dose adjustments.*
FDA Label Image

Figure 3 (Edarbyclor 08)

Figure 3 (Edarbyclor 08)
FDA Label Image

Principal Display Panel (40 mg/12.5 mg Tablet Bottle Label)

Principal Display Panel (40 mg/12.5 mg Tablet Bottle Label)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.